Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q301 Cream in mild to moderate atopic dermatitis
NCT03571620Phase 2Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Jun 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Q301 in atopic dermatitis (AD) (3 arms), sponsored by Qurient Co., Ltd. Primary endpoint: Proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and at least a two grade improvement at 8 weeks. Started Jun 2018; status: completed.
02
Drugs
Q301
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03571620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571620.